Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.
Michael D. Offin, MD
Advertisement
Articles by Michael D. Offin, MD
Michael D. Offin, MD, discusses the potential implications of introducing biosimilars into the field of oncology.
Advertisement
Latest Updated Articles
Dr. Offin on Potential Implications of Introducing Biosimilars Into OncologyPublished: October 22nd 2019 | Updated:
Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLCPublished: November 12th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5